Login
$NGNE
$23.30 +$0.00 (0.0%) After hours

$NGNE 8-K/A SEC Filings

Filed On Filing
23 Jan 2023 8-K/A: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1.1: Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors (the “Board”) of Neoleukin Therapeutics, Inc. (the...

17 Dec 2019 8-K/A: Financial Statements and Exhibits

We consent to the incorporation by reference in Registration Statement Nos. 333-194490, 333-203179, 333-210172, 333-216572, 333-223589 and 333-234734 on Form S-8 and Nos. 333-203180, 333-208651, 333-215457 and 333-223584 on Form S-3 of o...

11 Oct 2019 8-K/A: Financial Statements and Exhibits

On August 8, 2019, Aquinox Pharmaceuticals, Inc. (“Aquinox”), completed its acquisition of Neoleukin Therapeutics, Inc., a Delaware corporation (“Former Neoleukin”), pursuant to the terms of an Agreement and Plan of Merger (the “Merger A...

07 Aug 2015 8-K/A: Other Events

Vancouver, British Columbia - August 6, 2015 - (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of infl...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support